Boehringer Ingelheim Launches Metalyse® 25 mg in Egypt Following Approval by the Egyptian Drug Authority
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has announced the introduction of Metalyse® 25 mg (Tenecteplase) in Egypt as a treatment for acute ischemic stroke (AIS), following its recent approval by the Egyptian Drug Authority. Egypt is the second country